Pasithea Therapeutics' PAS-004 Receives FDA Rare Pediatric Disease Designation for Neurofibromatosis Type 1 Treatment

Key Takeaways

• FDA grants Rare Pediatric Disease Designation to PAS-004 for Neurofibromatosis Type 1 treatment
• Designation provides regulatory advantages including potential priority review voucher worth millions
• PAS-004 is a next-generation macrocyclic MEK inhibitor targeting serious genetic disorder affecting children

---

Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced today that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation (RPDD) to PAS-004 for treating Neurofibromatosis Type 1 (NF1), marking a significant regulatory milestone for the clinical-stage biotechnology company.

What is Rare Pediatric Disease Designation?

The FDA’s RPDD program supports development of treatments for serious or life-threatening diseases primarily affecting children under 18 years old. This designation provides several regulatory advantages, including potential eligibility for a Priority Review Voucher upon drug approval, which can be worth tens of millions of dollars when sold to other pharmaceutical companies.

Understanding Neurofibromatosis Type 1

Neurofibromatosis Type 1 is a genetic disorder affecting approximately 1 in 3,000 births worldwide. The condition causes tumors to grow along nerves and can lead to learning disabilities, bone deformities, and increased cancer risk. Current treatment options remain limited, creating significant unmet medical need for pediatric patients.

PAS-004: Next-Generation MEK Inhibitor

PAS-004 represents a novel approach as a macrocyclic MEK inhibitor designed to target the molecular pathways involved in NF1. MEK inhibitors work by blocking specific proteins that promote tumor growth, offering potential therapeutic benefits for patients with this challenging genetic condition.

Market and Clinical Implications

This FDA designation strengthens Pasithea’s position in the rare disease market and may accelerate clinical development timelines. The company can now leverage expedited regulatory pathways and increased FDA guidance throughout the drug development process.

For investors, the RPDD represents validation of PAS-004’s therapeutic potential and provides additional value through the priority review voucher opportunity. The designation also enhances the company’s ability to secure partnerships and funding for continued clinical trials.

Next Steps

Pasithea will continue advancing PAS-004 through clinical development while working closely with FDA regulators. The company expects to provide updates on trial enrollment and regulatory milestones throughout 2026.

---

Frequently Asked Questions

What does Rare Pediatric Disease Designation mean for NF1 patients?

This designation accelerates PAS-004’s development timeline and provides FDA support, potentially bringing this treatment to pediatric NF1 patients faster than traditional drug development pathways.

When will PAS-004 be available for patients?

PAS-004 is still in clinical development. While the RPDD expedites the process, patients will need to wait for successful clinical trials and FDA approval, which typically takes several years.

How does PAS-004 differ from existing NF1 treatments?

PAS-004 is a next-generation macrocyclic MEK inhibitor specifically designed for NF1, potentially offering improved efficacy and safety compared to current limited treatment options for this rare genetic disorder.